Dongcheng Biochemicals announced that its subsidiary, Lanacine Pharmaceuticals, has received the clinical trial approval document for 177Lu-LNC1011 injection drug from the US FDA and will conduct Phase I clinical trial in the near future. 177Lu-LNC1011 injection is a targeted radiopharmaceutical for intra-treatment of PSMA and is intended for the treatment of advanced prostate cancer patients with PSMA positive expression. Up to now, the relevant project has accumulated research and development expenses of approximately 15.2245 million yuan.
东诚药业：下属公司获药物临床试验批准
Yantai Dongcheng Biochemicals: subsidiary company's drug clinical trial approval obtained
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.